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Identity 
Other names: BLIMP-1, BLIMP1, PRDI-BF1 




The gene encompasses 23,6 kb DNA in humans, from 
106534195 to 106557814 (hg19-Feb, 2009) in the long
arm of chromosome 6. It encodes 7 exons. The open 
reading frame spans all 7 exons. 
Transcription 
The mRNAs encoded by PRDM1 have two transcript 
isoforms, PRDM1alpha and PRDM1beta, which are 
5164 and 4675 bp long, respectively. The shorter 
isoform is generated by usage of the alternative 
promoter located in intron 3 and contains a different 5' 
untranslated region. It lacks the 5' inframe portion of 
the coding region present in PRDM1alpha. A deletion 
exon 6 (exon 7 in mice) variant has also been described 



















PRDM1alpha is the larger isoform and contains 825 
amino acids, with a predicted molecular weight of 92 
kD. It has a PR domain at the N-terminal portion (86-
207 aa) of the protein, which is related to the SET 
domain (SM00317, SMART) found in many histone 
methyltransferases. In contrast to bona fide SET-
domain proteins, the PR domain in PRDM1 does not 
possess intrinsic histone methyltransferase activity. 
Five C2H2-type zinc fingers (SM00355, SMART), 
which represent the DNA binding domain, are present 
at the C-terminal portion of the protein (575-707 aa). 
The middle part of PRDM1 (about 300-400 aa) is rich 
in proline and serine. PRDM1beta lacks the N-terminal 
101 amino acids of the PRDM1alpha, and has a 
truncated PR domain. PRDM1beta has been shown to 
be functionally impaired in its transcriptional 
repression activity (Gyory et al., 2003). The proximal 3 
zinc fingers in PRDM1/Blimp-1 delta exon 6 variant 
are disrupted (Schmidt et al., 2008). This protein 
variant has auto-regulatory potential through negative 
regulation of PRDM1/Blimp-1 expression and 
functions. 
Expression 
PRDM1/Blimp-1 is expressed in several tissues and 
organs, including hematopoietic tissues, skin, central 
nervous system, testis and gut. Within the 
hematopoietic system, PRDM1/Blimp-1 is expressed in 
plasma cells, B cells, T cells, natural killer cells, 
monocytes, granulocytes and dendritic cells. In the B 
cell population, PRDM1/Blimp-1 starts to be expressed 
when they are committed to undergo terminal 
differentiation (Cattoretti et al., 2005). Consistent with 
its expression in normal lymphoid cells, PRDM1 is also 
expressed in 100% of multiple myeloma, and in various 
frequency in B and T lymphomas (Garcia et al., 2006; 
D'Costa et al., 2009). PRDM1/Blimp-1 expression is 
regulated by a number of transcription activators and
repressors (Martins and Calame, 2008). MicroRNAs 
have also been implicated in the down-regulation of 
PRDM1 in both normal germinal center B cells 
(Malumbres et al., 2009; Zhang et al., 2009; Gururajan 
et al., 2010) and in neoplastic lymphoid cells (Nie et 
al., 2008; Nie et al., 2010). Among PRDM1 isoforms, 
PRDM1alpha is the most abundantly expressed, 
although relative abundance between PRDM1alpha and 
PRDM1beta may vary between cell types (Garcia et al., 
2006). PRDM1/Blimp-1 delta 6 isoform is 





Mechanisms of action 
PRDM1/Blimp-1 is a transcription repressor that binds 
to specific DNA sequences through its zinc fingers, and 
functions as a scaffold for recruiting co-repressor that 
catalyze histone modifications. It has no known 
intrinsic histone methyltransferase activity. 
PRDM1/blimp-1 has been shown to mediate 
transcriptional silencing via interactions with H3 lysine 
methyltransferase G9a (Gyory et al., 2004), histone 
deacetylases HDAC1 and HDAC2 (Yu et al., 2000), 
and H3 lysine demethylase LSD1 (Su et al., 2009). 
PRDM1 can also tether Groucho family of transcription 
factors to mediate repression of gene transcription (Ren 
et al., 1999). Interaction of PRDM1/Blimp-1 with these 
co-repressors is mediated through the proline/serine 
rich domain and/or the zinc fingers. PRDM1 exerts its 
biological functions by repressing expressions of 
various target genes, which can be cell-type specific. 
For example, PRDM1/Blimp-1 mediates cell-cycle 
arrest in B cells by repressing c-myc, and in CD4 
positive helper T cells by inhibiting expressions of IL-2 
and Fos, an IL-2 activator (Martins and Calame, 2008). 
Biologic functions 
PRDM1 was originally identified as a novel repressor 
of human beta-interferon gene expression called PRDI-
BF1 (positive regulatory domain I binding factor 1)
(Keller and Maniatis, 1991). Later Blimp-1 (B 
lymphocyte-induced maturation protein), which 
represents the murine homolog of PRDI-BF1(Huang, 
1994), was discovered as a protein the enforced 
expression of which was sufficient to drive plasma cell
differentiation of a mouse lymphoma cell line with an
activated B cell phenotype (Turner et al., 1994). 
Studies since then have revealed a role of 
PRDM1/Blimp-1 in multiple cell types. 
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PRDM1/Blimp-1 is the master regulator of plasma cell
differentiation, critical for the generation of 
immunoglobulin-secreting plasma cells and 
maintenance of long-lived plasma cells (Shapiro-Shelef 
et al., 2003; Shapiro-Shelef et al., 2005; Martins a d 
Calame, 2008). It mediates terminal B cell 
differentiation by extinguishing gene programs related 
to B cell signaling and proliferation (Shaffer et al., 
2002), and allowing induction of XBP1 which 
coordinates phenotypic changes, including expansion 
of endoplasmic reticulum and increased protein 
synthesis, that define the plasma cell phenotype 
(Shaffer et al., 2004). 
PRDM1/Blimp-1 is also required for T cell 
homeostasis (Kallies et al., 2006; Martins et al., 2006; 
Calame, 2010). It attenuates proliferation and survival 
of CD4 positive helper T cells by repressing IL-2-
dependent activation; inhibits Th1 differentiation by 
down-regulating IFNgamma, Tbx21 and BCL6; and 
antagonizes BCL6-dependent follicular T cell 
differentiation. PRDM1/Blimp-1 also plays critical role 
in the differentiation of CD8-positive T cells. 
Besides its critical functions in B and T cells, 
PRDM1/Blimp-1 promotes differentiation of 
macrophages (Chang et al., 2000). It is also important 
for homeostatic development of dendritic cells as well 
as dendritic cell maturation (Chan et al., 2009). 
PRDM1/Blimp-1 negatively regulates NK cell 
activation by suppressing effector cytokine production 
(Smith et al., 2010). 
In the non-hematopoietic cell types, PRDM1/Blimp-1 
plays an important role in the terminal differentiation of 
keratinocytes (Magnusdottir et al., 2007) and sebacous 
cells (Sellheyer and Krahl, 2010). It also regulates 
postnatal reprogramming of intestinal enterocytes 
(Harper et al., 2011). 
Furthermore, PRDM1/Blimp-1 is required in 
embryonic developmental cell fate specification and 
organ morphogenesis, as demonstrated by mouse and 
zebrafish model systems (Bikoff et al., 2009). Blimp-1 
specifies cell fate of primordial germ cells (Vincet et 
al., 2005), neural crests and neuron progenitors (Roy 
and Ng, 2004), and also muscle fiber identity 
(Baxendale et al., 2004; Hofsten et al., 2008). Blimp-1 
is also critical for the normal development of the 
cardiovascular system, forelimbs and vibrissae 
(Robertson et al., 2007). 
Homology 
PRDM1 is conserved in chimpanzee, dog, cow, mouse, 
rat, chicken and zebrafish. 
Mutations 
Somatic 
Somatic mutations have been identified in diffuse large 
B cell lymphomas (DLBCL) at a frequency of about 8 
to 23% (Tam et al., 2006; Pasqualucci et al., 2006; 
Mandelbaum et al., 2010). One group did not detect 
mutations in 82 cases of DLBCLs in the Chinese 
population, suggesting geographic differences in 
PRDM1 mutations in DLBCL (Liu et al., 2007). 
PRDM1 mutations are exclusively detected in about 24 
to 35% of the activated B cell(ABC)/non-germinal 
center B cell (non-GCB) subtype of DLBCL, and have 
not been identified in GCB-like DLBCL. In addition, 
about 20% of primary DLBCL of the central nervous 
system, a subtype of DLBCL, harbor PRDM1 
mutations (Courts et al., 2008). PRDM1 mutation was 
also found in one case of primary effusion lymphoma 
out of 2 cases analyzed (Tate et al., 2007). The typ s of 
somatic mutations seen in PRDM1 include splice site 
mutations, frameshift insertion/deletion and less 
frequently, nonsense and missense mutations. The vast 
majority of these mutations result in inactivating 
truncations lacking one or more of the critical domains 
including PR, proline rich region, and the zinc fingers. 
Missense mutations have been demonstrated to affect 
PRDM1 functions (Mandelbaum et al., 2010). Most of 
the somatic mutations (about 90%) are associated with 
inactivation of the other allele by deletion, consistent 
with biallelic inactivation characteristic of a tumor 
suppressor gene. Mutations in acute leukemias and 
solid tumors have been not identified (Hangaishi and
Kurokawa, 2010). 
Implicated in 
Diffuse large B cell lymphomas 
Prognosis 
Diffuse large B cell lymphoma (DLBCL) with partial 
plasmablastic differentiation, as indicated by PRDM1 
expression, has a worse overall and failure free survival 
compared to conventional DLBLC without PRDM1 
expression, suggesting that PRDM1 may be useful as a 
prognostic marker in DLBCL (Montes-Moreno et al., 
2010). 
Expression of PRDM1beta has been implicated as a 
poor prognostic marker in DBLCL treated with CHOP 
(but not R-CHOP) and in T cell lymphomas. Resistance 
to chemotherapeutic agents mediated by PRDM1beta 
has been proposed as a potential mechanism (Liu et al., 
2007; Zhao et al., 2008). 
Oncogenesis 
Inactivation or down-regulation of PRDM1 appears to 
be an important event in the pathogenesis of DLBCLs 
of the ABC/non-GCB subtype. In about 50% of 
DLBCLs of this subtype, PRDM1 is inactivated by 
truncating or missense mutations, biallele gene 
deletions or transcription repression by a constitutively 
active, translocated BCL6 (Mandelbaum et al., 2010). 
In non-GCB/ABC-like DLBCL without these genetic 
lesions, asynchronous PRDM1 mRNA and protein 
expressions have been observed, suggesting a post-
transcriptional down-regulation (Mandelbaum et al., 
2010; Nie et al., 2010). MicroRNAs have been 
postulated as a potential mechanism of down-regulation 
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(Nie et al., 2010). All these findings are consistent with 
a tumor suppressor role of PRDM1 in DLBCL. In 
addition, PRDM1/Blimp-1 has been directly 
demonstrated in mouse models to function as a tumor 
suppressor gene (Calado et al., 2010; Mandelbaum et 
al., 2010). Mice lacking PRDM1/Blimp-1 are 
predisposed to develop lymphoproliferative disorders 
resembling human ABC-like DLBCL. One of these 
mouse models also demonstrated a cooperative 
pathogenic effect between PRDM1 inactivation and 
constitutive NF-kB activation. These findings suggest 
that PRDM1 inactivation contributes to the 
pathogenesis of ABC-like DLBCL by inhibiting 
terminal B cell differentiation induced by constituve 
canonical NF-kB activation characteristically present in 
this lymphoma type. 
Natural killer cell neoplasms 
Oncogenesis 
PRDM1 is frequently (about 40%) deleted as part of a 
minimal deleted region in aggressive natural killer 
(NK) cell neoplasms such as extranodal NK/T cell 
lymphomas, nasal type, and aggressive NK cell 
leukemias (Iqbal et al., 2009; Karube et al., 2011). This 
deletion is generally associated with a down-regulation 
of PRDM1 expression, associated with focal 
hypermethylation of the 5' region of the other PRDM1 
allele. Enforced expression of PRDM1 in NK 
lymphoma cell lines results in cell cycle arrest and 
apoptosis (Karube et al., 2011). Inactivating nonsense 
mutations have also been found in two NK cell lines 
and one clinical NK neoplasm (Iqbal et al., 2009; 
Karube et al., 2011). These findings indicate a tumor 
suppressor role of PRDM1 in NK cell neoplasms. 
Radiation-therapy induced second 
malignant neoplasms 
Prognosis 
Pediatric Hodgkin lymphoma patients treated by 
radiation are at risk of developing second malignancies 
later in life. Two SNP variants were identified at 6q21 
(intergenic between ATG5 and PRDM1) in a genome 
wide association study that are associated with 
increased risk of second neoplasms for pediatric 
patients with Hodgkin lymphoma who received 
radiation therapy. These variants correlate with 
decreased basal PRDM1 expression and reduced 
PRDM1 induction after radiation therapy, implicating 
PRDM1 in the etiology of radiation-therapy induced 
second malignancies (Best et al., 2011). 
Plasma cell myeloma 
Oncogenesis 
PRDM1 is consistently expressed in plasma cell 
myeloma. A plasmacytoma transgenic mouse model 
demonstrates that PRDM1/Blimp-1 is not a tumor 
suppressor gene in myeloma. Instead, it appears to be a 
limiting factor in plasma cell transformation (D'Costa 
et al., 2009). Reducing PRDM1/Blimp-1 dosage 
decreases incidence of plasmacytoma in mice but does
not cause reduction of normal plasma cells in 
nontransgenic mice. Loss of PRDM1/Blimp-1 
eliminates plasmacytoma development. 
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